LynxDx: MyProstateScore 2.0 (MPS2)

LynxDx launched MyProstateScore 2.0 (MPS2), a noninvasive, genomically driven 18-biomarker urine prostate cancer screening test meant to help guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings through stratified risk assessments. MPS2 serves as a standalone biomarker test for biopsy-naive patients, while for patients with a prior negative biopsy, it includes relevant clinical factors specific to a patient in the algorithm.